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Abstract
Background: The immune parameters of HIV/AIDS vaccine candidates that might be relevant in protection against HIV-1
infection are still undefined. The highly attenuated poxvirus strain MVA is one of the most promising vectors to be use as
HIV-1 vaccine. We have previously described a recombinant MVA expressing HIV-1 Env, Gag, Pol and Nef antigens from
clade B (referred as MVA-B), that induced HIV-1-specific immune responses in different animal models and gene signatures
in human dendritic cells (DCs) with immunoregulatory function.
Methodology/Principal Findings: In an effort to characterize in more detail the immunogenic profile of MVA-B and to
improve its immunogenicity we have generated a new vector lacking two genes (A41L and B16R), known to counteract host
immune responses by blocking the action of CC-chemokines and of interleukin 1b, respectively (referred as MVA-B DA41L/
DB16R). A DNA prime/MVA boost immunization protocol was used to compare the adaptive and memory HIV-1 specific
immune responses induced in mice by the parental MVA-B and by the double deletion mutant MVA-B DA41L/DB16R. Flow
cytometry analysis revealed that both vectors triggered HIV-1-specific CD4
+ and CD8
+ T cells, with the CD8
+ T-cell
compartment responsible for .91.9% of the total HIV-1 responses in both immunization groups. However, MVA-B DA41L/
DB16R enhanced the magnitude and polyfunctionality of the HIV-1-specific CD4
+ and CD8
+ T-cell immune responses. HIV-1-
specific CD4
+ T-cell responses were polyfunctional and preferentially Env-specific in both immunization groups.
Significantly, while MVA-B induced preferentially Env-specific CD8
+ T-cell responses, MVA-B DA41L/DB16R induced more
GPN-specific CD8
+ T-cell responses, with an enhanced polyfunctional pattern. Both vectors were capable of producing
similar levels of antibodies against Env.
Conclusions/Significance: These findings revealed that MVA-B and MVA-B DA41L/DB16R induced in mice robust,
polyfunctional and durable T-cell responses to HIV-1 antigens, but the double deletion mutant showed enhanced
magnitude and quality of HIV-1 adaptive and memory responses. Our observations are relevant in the immune evaluation of
MVA-B and on improvements of MVA vectors as HIV-1 vaccines.
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Introduction
The AIDS pandemic caused by the human immunodeficiency
virus (HIV-1) is spreading worldwide, with high impact and
severity in human health. The number of new infections and
deaths caused by AIDS disease are increasing each year, and is
particularly dramatic in developing or undeveloped countries.
Therefore, the finding of an effective vaccine against HIV-1 that
could control the infection and disease progression should be one
of the main priorities of the developed world.
An effective HIV-1 vaccine against AIDS should, in principle,
stimulate both humoral and cellular immune responses to multiple
viral antigens, including structural and regulatory proteins, and to
induce strong, broad, polyfunctional and durable responses
[1,2,3,4]. Due to the difficulty in obtaining immunogens capable
of inducing high titer neutralizing antibodies with broad
specificities, a focus on cellular immune responses has been one
of the main efforts in developing HIV-1 vaccines. In non-human
primates there is a good correlation between vaccine-induced
HIV-1-specific cellular immunogenicity and protection after a
challenge with a pathogenic simian/human immunodeficiency
virus (SHIV) [1,3,4], where CD8
+ T cells play an important role in
immunity to HIV-1 [4]. However, it has not been established what
immunological parameters are required for protection against
HIV-1 infection. This has been particularly noticeable after
knowing the results of the phase III Thai clinical trial where
modest protection of about 31% against HIV-1 infection was
observed in vaccinees with the combination of recombinant
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of reduced T-cell responses against HIV-1 [5]. Significantly, the
Thai trial suggests that improved poxvirus recombinants should be
considered as components of an effective HIV/AIDS vaccine.
Many vectors have been developed to improve HIV-1 specific
immune responses in animal models and humans. Some of the
most promising vectors are the highly attenuated vaccinia virus
strains, modified vaccinia virus Ankara (MVA) and New York
vaccinia virus (NYVAC) [6]. This is due to their excellent safety
profile, strong immunogenicity to HIV-1 antigens in animal
models, protective immune response after SHIV challenge and
strong, broad, polyfunctional and durable immune responses to
HIV-1 antigens in human trials ([3,7,8,9,10], for a review [11]).
We have previously described a recombinant MVA expressing
codon-optimized Env as monomeric gp120 and the polyprotein
Gag-Pol-Nef of HIV-1 from clade B (referred as MVA-B), that in
DNA prime/MVA boost protocols induced in mice strong
immune response to the HIV-1 antigens [7]. In macaques, a
similar MVA construct expressing Env (gp120 from SHIV89.6P)
and Gag-Pol-Nef (from SIVmac239) showed strong specific CD4
+
and CD8
+ T-cell immune responses with a bias for CD8
+, and
high protection after challenge with SHIV89.6P [3]. Furthermore,
the expression of HIV-1 antigens from MVA-B selectively induced
in human dendritic cells the expression of different cellular genes
that might act as regulators of immune responses to HIV-1
antigens [12]. Based on these previous results, MVA-B has
recently entered a phase I clinical trial in healthy volunteers in
Spain.
Although MVA recombinants are currently in clinical trials
against pathogens and tumors [11] more efficient vectors that
enhance the magnitude, breath, polyfunctionality and durability of
the immune responses to HIV-1 antigens are desirable. The MVA
genome lacks multiple genes, totaling almost 30 kb, as a result of
over 570 passages in chick embryo fibroblast cells [13]; however,
the vector still retains other viral genes with immunomodulatory
function that block components of the host response to infection
[14,15,16]. In fact, MVA recombinants lacking viral genes, which
antagonize host specific immune responses, have been generated
and some immunological benefit has been observed. Thus,
deletion of certain MVA genes, such as the viral interleukin 1b
binding protein (encoded by gene B15R in the Western Reserve
(WR) strain, B16R in the Copenhagen strain or its equivalent gene
MVA 184R in MVA) [17] or the gene A41L (MVA 153L) which
encodes a secreted glycoprotein that binds some CC-chemokines
[18,19,20,21], resulted in viruses that when inoculated in mice
showed enhanced immunogenicity against the viral vector.
In light of the need for the development of poxvirus vectors with
the capacity to induce strong, broad, polyfunctional and durable
immune responses to HIV-1 antigens, in this investigation we have
examined in detail the immunological behaviour of the vector
MVA-B and compared it with the immunogenicity elicited by a
double deletion mutant in both A41L and B16R genes (referred as
MVA-B DA41L/DB16R), to assess whether the MVA-B immune
response to HIV-1 antigens can be improved. Our findings in mice
using a DNA prime/MVA boost protocol demonstrate a strong
immunogenicity profile of MVA-B and MVA-B DA41L/DB16R.
Both vectors induced HIV-1-specific CD4
+ and CD8
+ T-cell
adaptive and memory immune responses, mostly mediated by
CD8
+ T cells. However, the deletion of the two viral immuno-
modulatory genes A41L+B16R significantly improves the magni-
tude of the HIV-1-specific CD4
+ and CD8
+ T-cell adaptive and
memory responses. HIV-1-specific CD4
+ T-cell responses induced
by both immunization groups were polyfunctional and preferen-
tially Env-specific. Furthermore, MVA-B induced an immunodo-
minance of Env-specific CD8
+ T-cell responses, while MVA-B
DA41L/DB16R induced preferentially GPN-specific CD8
+ T-cell
responses, with an enhanced polyfunctional pattern. Finally, both
vectors triggered similar levels of antibodies against HIV-1 Env.
Thus, MVA-B can improve its immunogenicity to HIV-1 antigens
by the double deletion of A41L and B16R viral genes and this
double mutant is an attractive candidate vector as an HIV-1
vaccine.
Results
Generation and in vitro characterization of MVA-B
DA41L/DB16R
An MVA-B deletion mutant lacking vaccinia virus genes A41L
and B16R (termed MVA-B DA41L/DB16R), whose products act
as inhibitors of CC-chemokines and IL-1b, was constructed as
detailed under Materials and Methods, from the previously
described recombinant MVA-B (expressing HIV-1 Env, Gag,
Pol and Nef antigens from clade B) [7]. The diagram of the
parental and deletion mutant is shown in Figure 1A. PCR using
primers for the A41L and B16R locus confirmed the absence of
these two genes in the MVA-B DA41L/DB16R genome, and their
presence in MVA-B (Figure 1B). In addition, analysis by Western
blot confirmed that MVA-B DA41L/DB16R expresses HIV-1
antigens BX08gp120 and IIIBGPN at the same level as their parental
virus MVA-B (Figure 1C). Viral growth kinetics showed that
deletion of A41L and B16R genes in the MVA-B genome does not
affect virus replication and hence, these two genes are not essential
for virus propagation in cultured cells (Figure 1D).
MVA-B DA41L/DB16R enhanced the magnitude and
polyfunctionality of HIV-1-specific CD4
+ and CD8
+ T-cell
adaptive immune responses
Since DNA prime/MVA boost immunization is an effective
protocol to activate T-cell responses to HIV-1 antigens
[1,2,3,7,22], we analyzed the HIV-1-specific immune responses
triggered in BALB/c mice by a DNA-B/MVA-B immunization
regimen, and compared it with that triggered by the double
deletion mutant MVA-B DA41L/DB16R. For this purpose groups
of mice were first primed intramuscularly (i.m.) with 100mgo f
DNA-B, and two weeks later the animals were boosted by
intraperitoneal (i.p.) route with 1610
7 PFU/mouse of recombi-
nant viruses MVA-B or MVA-B DA41L/DB16R. Animals primed
with sham DNA (DNA-w) and boosted with the non-recombinant
MVA-WT were used as control group (a diagram is shown on top
of Figure 2). Vaccine-elicited adaptive immune responses in
splenocytes were measured 11 days after the boost by fresh IFN-c
ELISPOT and ICS assays.
The IFN-c ELISPOT assay, shown in Figure 2A, revealed that
MVA-B DA41L/DB16R induced similar splenic T-cell responses
against Gag-B (HIV-1 peptide representative of Gag antigen), in
comparison with mice immunized with MVA-B. Non-recombi-
nant MVA-WT, used as a control, did not induce HIV-1-specific
responses.
To determine if immunological differences were observed
between the vectors, we analyzed in more detail the phenotype
of the adaptive immune response elicited by DNA-B/MVA-B and
DNA-B/MVA-B DA41L/DB16R immunization groups, by poly-
chromatic flow cytometry using ICS. To this end, we evaluated
IFN-c, TNF-a and IL-2 after in vitro stimulation with different
HIV-1 peptide pools that covered the entire HIV-1 sequences
present in the poxvirus vector (Env-pool, Gag-pool and GPN-
pool). As shown in Figure 2B, at 11 days post-boost, both DNA-B/
MVA-B and DNA-B/MVA-B DA41L/DB16R immunization
HIV/AIDS Vaccines
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+ and CD8
+ T-cell responses
(determined as the sum of the individual responses obtained for
Env, Gag and GPN peptide pools: Env-pool+Gag-pool+GPN-
pool). The overall HIV-1-specific immune response was mainly
mediated by CD8
+ T cells (.91.9%) in both immunization
groups, indicating that DNA/MVA preferentially elicited CD8
+
T-cell responses, as previously described in macaques [3].
Furthermore, DNA-B/MVA-B DA41L/DB16R induced a signif-
icant enhancement of 2.65-fold (p,0.005) and 2.89-fold
(p,0.005) in the magnitude of the total HIV-1-specific CD4
+
and CD8
+ T-cell responses, respectively. Significantly, some
differences in the frequencies of CD4
+ and CD8
+ T-cell responses
were observed between both groups. HIV-1-specific CD4
+ T-cell
responses were preferentially Env-specific in both immunization
groups (63.7% in DNA-B/MVA-B vs. 100% in DNA-B/MVA-B
DA41L/DB16R) (Figure 2C). However, while DNA-B/MVA-B
induced Env-specific and GPN-specific CD8
+ T-cell responses
(50.4% and 49.6%, respectively), DNA-B/MVA-B DA41L/
DB16R induced preferentially GPN-specific CD8
+ T-cell respons-
es (95.6%) (Figure 2C). No significant Gag-specific CD4
+ and
CD8
+ T -cell responses were detected.
When we analyzed the specific responses induced by the HIV-1
peptide pools, we observed that Env-specific T-cell responses in
DNA-B/MVA-B were mainly induced by CD8
+ T-cells (88.7% vs.
29.6% in DNA-B/MVA-B DA41L/DB16R; with a higher
percentage of IFN-c and TNF-a secreting T cells than DNA-B/
MVA-BDA41L/DB16R, p,0.005), while in DNA-B/MVA-B
DA41L/DB16R the responses were mainly induced by CD4
+ T-
cells (70.4% vs. 11.3% in DNA-B/MVA-B; with a higher
percentage of IFN-c, TNF-a and IL-2 secreting T cells than
DNA-B/MVA-B, p,0.005) (Figure 3A). The GPN-specific T-cell
responses were mainly induced by CD8
+ T-cells in both
immunization groups (100% in DNA-B/MVA-B DA41L/
DB16R vs. 93.9% in DNA-B/MVA-B), however DNA-B/MVA-
B DA41L/DB16R induced a higher percentage of IFN-c, TNF-a
and IL-2 secreting T cells than DNA-B/MVA-B, (p,0.005)
(Figure 3B).
The simultaneous measurements of three functions allowed the
assessment of the quality of the vaccine-induced CD4
+ and CD8
+
T-cell responses. On the basis of the analysis of IFN-c, TNF-a and
IL-2 secretion, seven distinct HIV-1-specific CD4
+ and CD8
+ T-
cell populations were identified. To further characterize the
immunogenicity triggered in each immunized group, we assessed
polyfunctional T-cell responses. The results showed that DNA-B/
MVA-B DA41L/DB16R induced an enhancement in the poly-
functionality of HIV-1-specific CD4
+ and CD8
+ T-cell responses,
with 100% of CD4
+ T cells and 86.9% of CD8
+ T cells secreting
simultaneously 2 or 3 cytokines (Figure 3C).
The findings of Figures 2 and 3 revealed that the overall HIV-1-
specific adaptive immune response triggered by MVA-B and
MVA-B DA41L/DB16R was mainly mediated by CD8
+ T-cells.
However, some differences were noticeable between the vectors.
Immunization with DNA-B/MVA-B DA41L/DB16R enhanced
the magnitude and polyfunctionality of HIV-1-specific CD4
+ and
CD8
+ T-cell adaptive immune responses, with an immunodomi-
nance of GPN-specific CD8
+ T-cell responses. CD4
+ T-cell
responses induced by both vectors were Env-specific.
MVA-B DA41L/DB16R enhanced the magnitude of
long-lived memory HIV-1-specific T-cell responses, with a
similar polyfunctional pattern as MVA-B
Since memory T-cell responses might be critical for protection
against HIV-1 infection, we assessed at 53 days post-boost the
long-term immunogenicity profile elicited by DNA-B/MVA-B
and DNA-B/MVA-B DA41L/DB16R following the immunization
schedule described in the top of Figure 2.
Vaccine-elicited memory immune responses in splenocytes were
first measured by fresh IFN-c ELISPOT assay following
stimulation with HIV-1 peptide Gag-B. As shown in Figure 4A,
DNA-B/MVA-B DA41L/DB16R enhanced by 3.81-fold
(p,0.005) the splenic T-cell memory responses against Gag-B in
comparison with mice immunized with DNA-B/MVA-B. Non-
recombinant MVA-WT, used as a control, did not induce HIV-1-
specific responses.
Next we decided to evaluate in more detail the phenotype of the
HIV-1-specific memory T cells elicited by the immunization
groups DNA-B/MVA-B DA41L/DB16R and DNA-B/MVA-B.
Splenocytes were stained for CD4
+ and CD8
+ T cells, and we
evaluated by ICS IFN-c and IL-2 secretion after in vitro stimulation
with the HIV-1 peptide pools for Env, Gag and GPN. Similarly as
with the adaptive immune response (Figure 2B), the overall HIV-
1-specific immune response at 53 days post-boost was mainly
mediated by CD8
+ T cells (.93.7%) in both immunization groups
(Figure 4B). As shown in Figure 4B, long-term post-boost
immunization with DNA-B/MVA-B DA41L/DB16R induced a
higher magnitude of HIV-1-specific CD4
+ and CD8
+ T-cell
memory responses producing IFN-c and IL-2 than DNA-B/
MVA-B [CD4
+ memory T cells: 1.46% in DNA-B/MVA-B
DA41L/DB16R vs. 0.56% in DNA-B/MVA-B, (p,0.005); CD8
+
memory T cells: 21.66% in DNA-B/MVA-B DA41L/DB16R vs.
11.49% in DNA-B/MVA-B (p,0.005)]. Both vectors induced a
similar pattern of HIV-1-specific CD4
+ T-cell memory responses
(with preference towards Env) (Figure 4C). However, the pattern
of CD8
+ T-cell memory responses was different between the two
vectors: DNA-B/MVA-B DA41L/DB16R induced a higher
percentage of GPN-specific CD8
+ T-cell memory responses, while
DNA-B/MVA-B induced preferentially a higher percentage of
Env-specific CD8
+ T-cell memory responses (Figure 4C).
To have a detailed assessment of the quality of the T-cell
memory responses, we evaluated secretion of two cytokines (IFN-
c and IL-2) in HIV-1-specific CD4
+ and CD8
+ T cells (Figure 5).
In general, both immunization groups induced HIV-1-specific
CD4
+ and CD8
+ T memory cells with a similar polyfunctional
Figure 1. Characterization of MVA-B DA41L/DB16R recombinant virus. (A) Scheme of MVA-B and MVA-B DA41L/DB16R genome maps,
adapted from [13] and [57]. The different regions are indicated by capital letters. The right and left terminal regions are shown. Below each map, the
deleted or fragmented genes are depicted as black boxes. In MVA-B DA41L/DB16R the deleted A41L and B16R genes are indicated. The HIV-1 Gag-
Pol-Nef (from isolate IIIB) and gp120 (from isolate BX08) clade B sequences driven by the synthetic early/late (sE/L) virus promoter inserted within the
TK viral locus (J2R) are indicated, adapted from [7]. (B) PCR analysis of A41L and B16R locus. 100ng of viral DNA extracted from DF-1 cells infected at 2
PFU/cell with MVA-WT, MVA-B or MVA-B DA41L/DB16R was used for PCR analysis. The DNA products corresponding to the parental virus or to the
deletion are indicated by an arrow on the right, with the expected size in base pairs. Molecular size marker (1Kb ladder) with the corresponding sizes
(base pairs) is indicated on the left. Lane Mock, cells not infected. (C) Expression of HIV-1 BX08gp120 and IIIBGPN proteins in DF-1 cells infected (2 PFU/
cell) with MVA-B and MVA-B DA41L/DB16R, at 24h post-infection. Arrows on the right indicate the position of HIV-1 BX08gp120 and IIIBGPN proteins.
(D) Virus growth of MVA-B and MVA-B DA41L/DB16R in infected (0.01 PFU/cell) DF-1 cells at different times and titrated by plaque immunostaining
assay with anti-WR antibodies. The mean of three independent experiments are shown.
doi:10.1371/journal.pone.0012395.g001
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PLoS ONE | www.plosone.org 4 August 2010 | Volume 5 | Issue 8 | e12395Figure 2. HIV-1-specific adaptive immune responses induced by MVA-B and MVA-B DA41L/DB16R. (Upper) Scheme of the DNA prime/
MVA-boost immunization protocol used in this study. BALB/c mice were primed i.m with 100mg of DNA-B (50mg of pCMV-BX08gp120+50mgo f
pCDNA-IIIBGPN), or control DNA and two weeks later infected i.p with 1610
7 PFU of MVA-B, MVA-B DA41L/DB16R or MVA-WT. (A) Vaccine-elicited T-
cell responses of splenocytes 11 days after the last immunization with MVA-B, MVA-B DA41L/DB16R or MVA-WT, in a fresh IFN-c ELISPOT assay
following stimulation with HIV-1 peptide Gag-B. Bars represent the total number of Gag-B-specific IFN-c secreting cells per 10
6 splenocytes in each
group. Standard deviations from triplicate cultures are shown. *, represent statistically significant differences between groups, p,0.05. A
representative experiment out of two is shown. (B) Total HIV-1-specific CD4
+ and CD8
+ T-cell immune responses induced in mice 11 days after the last
immunization with DNA-B/MVA-B or DNA-B/MVA-B DA41L/DB16R, measured by flow cytometry using ICS assay, following stimulation with different
HIV-1 peptide pools that covered the entire HIV-1 sequence present in the poxvirus vector (Env-pool, Gag-pool and GPN-pool). The percentage of
HIV-1-specific CD4
+ and CD8
+ T-cell responses directed against Env-pool, Gag-pool and GPN-pool is indicated by different color codes, and the
frequencies were calculated as the addition of single, double and triple positive T cells for the secretion of IFN-c, TNF-a and IL-2; thus, each
responding cell was counted once. The background of the unstimulated controls was subtracted in all cases, and only significant values over the
background are represented. Standard deviations are shown. **, represent statistically significant differences between groups, p,0.005. (C) The pie
charts summarize the data of panel B, with each set representing the fraction of CD4
+ or CD8
+ T cells specific for Env-pool, Gag-pool and GPN-pool.
doi:10.1371/journal.pone.0012395.g002
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PLoS ONE | www.plosone.org 5 August 2010 | Volume 5 | Issue 8 | e12395Figure 3. Cytokine secretion and polyfunctionality of HIV-1-specific CD4
+ and CD8
+ T cells after 11 days post-boost with MVA-B and
MVA-B DA41L/DB16R. Mice were infected and splenocytes processed as described in Figure 2. (A and B) Percentages of CD4
+ and CD8
+ T cells
secreting IFN-c, TNF-a or IL-2, and directed against HIV-1 peptide pools Env-pool (A), and GPN-pool (B), and measured by ICS. The background of the
unstimulated controls was subtracted in all cases, and only significant values over the background are represented. Standard deviations are shown.
HIV/AIDS Vaccines
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31.6% and 56.1%). However, DNA-B/MVA-B DA41L/DB16R
induced a higher magnitude of polyfunctional CD4
+ and CD8
+ T
memory cells (Figure 5A). The percentage of polyfunctional Env-
specific CD8
+ T memory cells were higher in DNA-B/MVA-B
immunization group compared with DNA-B/MVA-B DA41L/
DB16R (2.82% vs. 1.37% of double CD8
+ T memory cells that
secreted IFN-c and IL-2, p,0.005). Gag-specific T memory cells
were low, thus polyfunctionality was not significant. The
percentage of polyfunctional GPN-specific CD8
+ T memory cells
were higher in DNA-B/MVA-B DA41L/DB16R immunization
group compared with DNA-B/MVA-B (5.54% vs. 0.72% of
double CD8
+ T memory cells that secreted IFN-c and IL-2,
p,0.005) (Figure 5B).
Figure 4. HIV-1-specific memory immune responses induced by MVA-B and MVA-B DA41L/DB16R. (A) Vaccine-elicited T-cell responses
of splenocytes 53 days after the last immunization with DNA-B/MVA-B or DNA-B/MVA-B DA41L/DB16R, in a fresh IFN-c ELISPOT assay following
stimulation with HIV-1 peptide Gag-B. Bars represent the total number of Gag-B-specific IFN-c secreting cells per 10
6 splenocytes in each group.
Standard deviations from triplicate cultures are shown. **, represent statistically significant differences between groups, p,0.005. A representative
experiment out of two is shown. (B) Total HIV-1-specific CD4
+ and CD8
+ T-cell memory immune responses against HIV-1 peptide pools Env-pool, Gag-
pool and GPN-pool, induced in mice 53 days after the last immunization with DNA-B/MVA-B or DNA-B/MVA-B DA41L/DB16R, and measured by ICS.
The percentage of HIV-1-specific CD4
+ and CD8
+ T memory cells for Env-pool, Gag-pool and GPN-pool is indicated by different color codes and the
frequencies were calculated as the addition of single and double positive T cells for the secretion of IFN-c and IL-2; thus, each responding cell was
counted once. The background of the unstimulated controls was subtracted in all cases, and only significant values over the background are
represented. Standard deviations are shown. **, represent statistically significant differences between groups, p,0.005. (C) The pie charts summarize
the data of panel B, with each set representing the fraction of CD4
+ or CD8
+ T memory cells specific for Env-pool, Gag-pool and GPN-pool. A
representative experiment out of two is shown.
doi:10.1371/journal.pone.0012395.g004
**, represent statistically significant differences between groups, p,0.005. Below the graphs, the percentage of CD4
+ and CD8
+ T cells (addition of
IFN-c+TNF-a+IL-2 CD4
+ or CD8
+ T-cells) specific for each HIV-1 peptide pool is depicted as pie charts. (C) Functional composition of vaccine-induced
CD4
+ and CD8
+ T cells specific for Env-pool+Gag pool+GPN-pool, based on the secretion of IFN-c, TNF-a and/or IL-2. All the possible combinations of
the responses are shown on the X axis, whereas the percentages of the functionally distinct cell populations are shown on the Y axis. Bars correspond
to the fraction of different functionally distinct T-cell population within total CD4
+ and CD8
+ population. Standard deviations are shown. **, represent
statistically significant differences between groups, p,0.005. Responses are grouped and color-coded on the basis of the number functions. The pie
chart summarizes the data and each slice of the pie correspond to the fraction of CD4
+ or CD8
+T cells with a given number of functions within the
total CD4
+ or CD8
+ T-cell populations. The size of the pie chart represents the magnitude of the specific HIV-1 immune response induced.
doi:10.1371/journal.pone.0012395.g003
HIV/AIDS Vaccines
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PLoS ONE | www.plosone.org 8 August 2010 | Volume 5 | Issue 8 | e12395The findings of Figures 4 and 5 established that the overall
HIV-1-specific memory immune response triggered by both
vectors was mainly mediated by CD8
+ T-cells. Immunization
with DNA-B/MVA-B DA41L/DB16R significantly increased the
magnitude of HIV-1-specific CD4
+ and CD8
+ T-cell memory
responses. HIV-1-specific CD4
+ T-cell memory responses were
preferentially Env-specific in both immunization groups. Howev-
er, DNA-B/MVA-B DA41L/DB16R induced an immunodomi-
nance towards CD8
+ GPN-specific T-cell memory responses,
while immunization with DNA-B/MVA-B induced preferentially
CD8
+ Env-specific T-cell memory responses. Finally, both
immunization groups induced a similar polyfunctional pattern.
MVA-B and MVA-B DA41L/DB16R induced antibodies
against HIV-1 gp120
Since all the viral vectors release monomeric gp120 from cells in
the course of virus infection [7], we also evaluated whether DNA-
B/MVA-B and DNA-B/MVA-B DA41L/DB16R immunization
groups elicited an antibody response against HIV-1 Env. This was
performed by ELISA using individual mouse serum from each
group of immunized animals at 11 and 53 days post-boost. As
shown in Figure 6A and 6B, between both immunization groups,
similar levels of specific antibodies reactive against gp160 protein
from the HIV-1 clone LAV (clade B) were observed at the
different times post-boost. Therefore, both immunization groups
induced humoral immune responses against HIV-1 Env and the
viral deletions did not affect the antibody levels.
Discussion
MVA-B, the attenuated vaccinia virus vector MVA expressing
the HIV-1 antigens Env, as monomeric gp120, and Gag, Pol and
Nef, as a polyprotein, from clade B, is considered a vaccine
candidate against HIV/AIDS [7], based on preclinical studies in
different animal models [3,7] and on gene signatures triggered in
human dendritic cells [12]. In fact, expression of HIV-1 proteins
from DCs infected with MVA-B induced the expression of
cytokines, cytokine receptors, chemokine receptors, and molecules
involved in antigen uptake and processing, including major
Figure 6. Humoral immune response elicited against HIV-1 gp160 protein induced by immunization with MVA-B and MVA-B
DA41L/DB16R. Serum from individually immunized mice was evaluated by ELISA for specific anti-gp120 antibodies in blood taken 11 (A) and 53 (B)
days after the last immunization with DNA-B/MVA-B, DNA-B/MVA-B DA41L/DB16R and DNA-w/MVA-WT, as described under Materials and Methods.
Serum from naı ¨ve (not immunized) animals served as control. Absorbance values (measured at 450 nm) correspond to 1/100 dilution of individual
serum, and each mouse is represented by a dot. A black dash line reveals the mean value for each group. A representative experiment out of two is
shown.
doi:10.1371/journal.pone.0012395.g006
Figure 5. Polyfunctionality of HIV-1-specific CD4
+ and CD8
+ T-cell memory responses induced by immunization with MVA-B and
MVA-B DA41L/DB16R. Polyfunctionality of HIV-1-specific CD4
+ and CD8
+ T memory cells against HIV-1 peptide pools Env-pool, Gag-pool and GPN-
pool, on the basis of IFN-c and IL-2 secretion, and induced in mice 53 days after the last immunization with DNA-B/MVA-B or DNA-B/MVA-B DA41L/
DB16R, and measured by ICS assay. (A) Functional composition of vaccine-induced CD4
+ and CD8
+ T memory cells specific for Env-pool+Gag
pool+GPN-pool, based on the secretion of IFN-c and/or IL-2. All the possible combinations of the responses are shown on the X axis, whereas the
percentages of the functionally distinct cell populations are shown on the Y axis. Bars correspond to the fraction of different functionally distinctT -
cell population within total CD4
+ and CD8
+ population. Standard deviations are shown. **, represent statistically significant differences between
groups, p,0.005. Responses are grouped and color-coded on the basis of the number functions. The pie chart summarizes the data and each slice of
the pie correspond to the fraction of CD4
+ or CD8
+T cells with a given number of functions within the total CD4
+ or CD8
+ T-cell memory populations.
The size of the pie chart represents the magnitude of the specific HIV-1 memory immune response induced. A representative experiment out of two
is shown. (B) Representative flow cytometry plots. The numbers indicate the percentage of memory CD4
+ or CD8
+ T cells expressing cytokine(s) IFN-c
and/or IL-2. The last sample (CD8
+ T memory cells GPN-specific induced after immunization with DNA-w/MVA-WT) was lost due to contamination, and
the one represented derives from another independent experiment, to show lack of response.
doi:10.1371/journal.pone.0012395.g005
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act as regulators of immune responses to HIV-1 antigens [12].
Therefore, based on these findings, a prophylactic phase I clinical
trial was initiated in Spain with MVA-B.
The MVA vector, despite of its attenuated phenotype, still
contains a number of genes that encode proteins that can interfere
with host immune responses [16]. It was previously described that
MVA with a single deletion in A41L [18] or in B16R [17,20] could
enhance the immunogenicity of the vector. Thus, to try to improve
the immunogenicity elicited by MVA-B, in this study we have
removed from the viral genome these two genes (A41L and B16R),
which encode proteins that interfere with the action of CC-
chemokines and IL-1b, respectively and generated a double
deletion mutant (MVA-B DA41L/DB16R). First, we showed in
cultured cells that MVA-B DA41L/DB16R efficiently produced
the four HIV-1 antigens (Env, Gag, Pol and Nef) in a stable
manner and at the same level as MVA-B in the course of virus
infection. Also, MVA-B DA41L/DB16R replicate similarly to
MVA-B in cultured cells, indicating that deletion of these genes,
has no effect on virus replication. Then, we carried out a detail
characterization of the immunological responses induced in mice
using DNA prime/MVA boost approach by the parental MVA-B
and by the deletion mutant MVA-B DA41L/DB16R. Because flow
cytometry analysis allows more extensive characterization of T-cell
effector functions at the single-cell level [23], we used ICS to
characterize the adaptive (11 days post-boost) and memory (53
days post-boost) HIV-1-specific immune responses induced in
mice. Since our interest is to develop MVA-B mutants with
enhanced immunogenicity to HIV-1 antigens, we focus our study
on a detail immunological analysis by ICS on the double deletion
mutant MVA-B DA41L/DB16R versus the parental MVA-B. Our
findings revealed that at 11 days post-boost the magnitude and
polyfunctionality of the total HIV-1-specific CD4
+ and CD8
+ T-
cell immune responses (specific for Env-, Gag- and GPN-peptide
pools) was significantly higher for MVA-B DA41L/DB16R than
for MVA-B. The vaccine-induced T-cell responses were predom-
inantly mediated by CD8
+ T cells in both immunization groups.
HIV-1-specific CD4
+ T-cell responses were preferentially Env-
specific in both immunization groups. Furthermore, immunization
with DNA-B/MVA-B DA41L/DB16R induced an immunodomi-
nance towards GPN-specific CD8
+ T-cell responses compared
with DNA-B/MVA-B. At 53 days post-boost, DNA-B/MVA-B
DA41L/DB16R triggered higher magnitude of CD4
+ and CD8
+
HIV-1-specific memory immune responses than DNA-B/MVA-B,
with a significant enhancement in the percentage of CD8
+ T
memory cells that are those that have been described to have a
powerful and direct antiviral capacity [24,25,26]. Again, as at 11
days post-boost, the vaccine-induced T-cell responses were
predominantly mediated by CD8
+ T cells, although CD4
+ T-cell
responses were also detected. Also, HIV-1-specific CD4
+ T-cell
memory responses were preferentially Env-specific in both
immunization groups. DNA-B/MVA-B DA41L/DB16R induced
preferentially GPN-specific CD8
+ T memory cells whereas DNA-
B/MVA-B induced an immunodominance of Env-specific CD8
+
T memory cells. Furthermore, the memory responses induced by
both immunization groups were similarly polyfunctional for the
secretion of IFN-c and IL-2.
In preclinical studies using DNA prime/poxvirus boost
immunization protocols with MVA expressing the HIV-1 antigens
Env, Gag, Pol and Nef, it was described an immunodominance of
Env-specific responses [3,7] This immunodominance was also
reported in a phase I clinical trial with DNA/NYVAC expressing
similar HIV-1 antigens but from clade C [10]. The question of
immunodominance of Env has not yet been answered experimen-
tally. The easiest explanation is that the Env protein is simply
more immunogenic than Gag-Pol-Nef and when Env and the
polyprotein are produced simultaneously in the infected cells (note
that both Env and GPN are driven by the same synthetic early/
late promoter but transcribed in opposite orientations) [7], antigen
presentation is more bias for Env than GPN, probably by
enhanced proteasome degradation of Env over GPN. However,
the above reasoning does not apply in the DNA-B/MVA-B
DA41L/DB16R immunization protocol in which a GPN response
is favoured over an Env response, while both antigens are well
expressed and the levels of antigen expression are similar. Thus,
differences in immunodominance are more likely due to the mode
of action of A41L and B16R genes playing a regulatory role in the
quality of immune responses.
A41L encodes a secreted glycoprotein of 30 kDa [27], that binds
CC-chemokines CCL21, CCL25, CCL26 and CCL28 [19,21].
The protein A41 blocks the interaction of CC-chemokines with
glycosaminoglycans on the endothelial cell surface and thereby
disrupts the establishment of a chemokine concentration gradient
around the site of infection. A41 is not essential for virus
replication in cell culture and its deletion does not affect virus
growth [27]. Deletion of A41L in the MVA genome enhances
immunogenicity to the vector and conferred better protection
against subsequent challenge with the pathogenic strain WR, thus
improving vaccine efficacy [18]. The nature of the chemokines
bound by A41 [19,21] could provide an explanation for the
increased immunogenicity of MVA-B DA41L/DB16R. CCL21 is
a pivotal molecule for priming T-cell responses, co-stimulating the
expansion of naı ¨ve CD4
+ and CD8
+ T cells and inducing Th1
polarization [28]. CCL25 is also involved in the formation of a T-
cell response [29], and CCL28 is expressed by the mucosal
epithelia of the gut, where it attracts CD4
+ and CD8
+ resting T
cells [30]. Therefore, the deletion of A41L gene from MVA-B
could permit to this subset of chemokines act in a way to stimulate
a T-cell response against the HIV-1 antigens.
The other immunomodulatory gene, B16R,e n c o d e sa
secreted glycoprotein of 50–60 kDa that is expressed at late
times of the infectious cycle, and it functions as a viral soluble
receptor for IL-1b (vIL-1bR) that blocks inflammatory and
febrile host responses to infection [31,32]. MVA expresses the
B16 protein [33] and deletion of B16R in the MVA genome
results in a virus with enhanced CD8
+ T-cell memory responses
to the virus in a mouse model [17,20], and after vaccination
MVA DB16R provides higher levels of protection against a
challenge with WR [17]. We do not know how the absence of
the viral soluble receptor for IL-1b enhanced immunogenicity
of MVA-B DA41L/DB16R, although improved functionality of
DCs has been proposed by the single deletion mutant of viral IL-
1bR [17]. IL-1b is an essential mediator of Fas-ligation-induced
maturation of murine DCs; and maturation of murine DCs
could be abrogated by the use of IL-1b-neutralizing antibodies,
which may function in a similar manner as the vIL1bR [34].
Thus, deletion of IL-1bR from MVA avoids the neutralization of
IL-1b, and subsequently may lead to improved functionality of
DCs to serve as antigen-presenting cells, which might result in
better T-cell memory responses. Similarly, it has been shown
that stimulation of endothelial cells with IL-1b resulted in
human inducible co-stimulator-ligand-mediated activation of
memory T cells [35]. The loss of neutralizing IL-1b activity
might be the functional basis for our findings that vaccination
with MVA-B DA41L/DB16R appeared predominantly to
improve memory T-cell responses, suggesting that the viral IL-
1bR could have a specific role in abrogating anti-viral memory
T-cell responses.
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above, it might be suggested that the shift towards GPN-response
triggered by the MVA double mutant is the combined result of
viral-induced chemokines that stimulate T-cell responses to the
HIV-1 antigens and to improved functionality of DCs to serve as
antigen presenting cells. Taking into consideration that during
infection gp120 is released from cells and GPN remains
intracellular and that the HIV-1 proteins expressed in MVA-B-
infected immature monocyte derived dendritic cells (IMDDC)
induced the expression of different immunomodulatory molecules
[12], it will not be surprising if the deletion of two viral genes
acting as inhibitors of an inflammatory response, might have a
profound effect on the shift of immune responses, with enhanced
GPN over Env response. The biological significance of these
findings is that enhanced Gag response has been associated with
better control of virus in macaques infected with SIV and in HIV-
1-infected individuals [36,37].
It is also notorious that MVA-B DA41L/DB16R enhanced the
total magnitude o the HIV-1-specific adaptive and memory
immune responses, but the CD8
+ T-cell responses elicited were
mainly directed against the HIV-1 peptide pool GPN, thereby
restricting the breadth of the HIV-1 immune response. While the
breath of the HIV-1-specific immune response is one of the
parameters that could be associated with better control of HIV-1
infection, we do not know how relevant this phenomenon is.
Further experiments need to be done in other animal models as
non-human primates to determine the possible benefits of the
response elicited by MVA-B DA41L/DB16R.
How significant are our findings with regard to immune
requirements for HIV-1 protection? While definition of correlates
of protection to HIV-1 remains to be firmly established, there are
a number of markers that can be used as potential indicators for an
effective HIV-1 vaccine, such as: 1) specific activation of CD4
+
and CD8
+ T cells; 2) triggering polyfunctional responses; 3)
enhanced magnitude and breath of the immune response; 4)
induction of long-term memory cells; 5) production of neutralizing
antibodies with broad specificities. A correlation of the CD8
+ T-
cell response with a lowering of peak viremia in acute HIV-1
infection has been described [38,39], and there are several features
of the T-cell response to HIV-1 that are correlated with control of
viral replication [40,41]. Several studies have demonstrated that
polyfunctionality is associated with protective antiviral immunity
[40,41,42,43,44]. In HIV-1-infected patients that are nonprogres-
sors, HIV-1-specific CD8
+ T cells were polyfunctional [40]. This
association suggests that polyfunctional CD8
+ T cells are an
important component of a protective immune response. It might
be relevant to highlight that we have obtained an immune
response triggered by the two MVA vectors that fulfil several of the
characteristics mentioned above for a candidate HIV-1 vaccine
(i.e, activation of CD4
+ and CD8
+ T cells, polyfunctional response,
enhanced magnitude of the immune response and induction of
long-term memory cells). Moreover, we have achieved a shift and
more balanced immune response to HIV-1 antigens than
previously observed, by the selective deletion of the viral genes
A41L+B16R.
Due to key differences in rodent and primate anatomy,
physiology, immune biology [45], reproduction, and inbreeding
[46], mice are considered as unreliable predictors of primate-
human and nonhuman-immune responses to HIV-1 vaccine
strategies (see also [47]). However, the use of mouse models has
special importance as a first step to describe and characterize the
impact of vectors on pathogenesis and host immune responses. In
fact, the role of selected viral genes in pathogenesis when deleted
from the vaccinia virus genome has been defined in mouse models,
and the course of smallpox disease was first characterized in the
mouse and shown similar phenotype to the human disease [48].
Moreover, the HIV-1 vaccine candidate developed in our
laboratory (MVA-B) was initially tested in mice in DNA prime/
MVA boost protocols showing specific immune responses to the
HIV-1 antigens Env and GPN, with immunodominance for Env
in both Balb/c mice and HLA-class I humanized mice [7]. A
similar immune profile was observed in macaques immunized in
DNA prime/MVA boost with a similar MVA vector as in mice
but expressing Env (gp120 from SHIV89.6P) and Gag-Pol-Nef
(from SIVmac239), revealing immunodominance for Env over
GPN, strong specific CD4
+ and CD8
+ T-cell immune responses
with a bias for CD8
+, and high protection after challenge with
SHIV89.6 [3]. Moreover, when a different vaccinia virus vector
NYVAC was used but expressing the same cassette as MVA-B, but
from subtype C, similar observations were obtained in mice [8,49],
macaques [50] and humans [10,50,51], with immunodominance
for Env, preferential activation of CD4
+ T cells and polyfunctional
responses. Clearly these experiments and microarray data [12]
demonstrated that MVA and NYVAC vectors behaved distinctly
in animal and human cells, with each virus maintaining a similar
profile in the different models. The promising results in mice and
NHP let us to start a Phase I clinical trial with MVA-B in healthy
human volunteers. Thus, detailed studies of mouse immune
responses to novel HIV-1 vaccine vectors can help preclinical
evaluations to optimize/compare HIV-1 immunogens or vaccine
strategies for future preclinical trials in NHP and subsequently in
human trials. As example, comparison of the immune response
elicited by DNA prime/poxvirus (MVA or NYVAC) in preclinical
(mouse and macaques) and clinical (human) trials conducted by
Eurovacc is shown as supplementary information (Table S1), to
indicate similarities in magnitude, breath and polyfunctional
responses in the three models. Whether or not these responses
are essential for the control of HIV-1 infection is not known, but
complementary information on the immune response triggered in
the three systems will help to define correlates of protection. The
more information we obtained on specific immune responses to
HIV-1 antigens and of vector impact in animal models the better
chances we have to develop a more effective HIV-1 vaccine in
humans.
In conclusion, this investigation has expanded our previous
observations on the immunogenicity of the HIV/AIDS vaccine
candidate MVA-B [7], providing a more detail characterization of
the HIV-1-specific immune responses. In addition, we demon-
strate that double deletion of viral genes encoding inhibitors of
CC-chemokines and of IL-1b on MVA-B is an efficient approach
to improve the immunogenicity of the vector against HIV-1
antigens. The immunological findings have been observed in two
independent experiments indicating a consistent immunoregula-
tory action of the vectors. Thus, the genetic manipulation of
MVA-B is an efficient strategy to expand the repertoire of T-cell
immune responses against HIV-1 antigens. Since the genome of
MVA contains genes encoding inhibitors of various cellular
pathways and some of these inhibitors act in concert, it might
be an important consideration in the improvement of the
immunogenicity of MVA to knock down viral genes that act on
various pathways, as we have shown here. The immunity elicited
by the double mutant could be relevant in protection against HIV-
1 infection, which should be explored in the macaque model. The
recent excitement in the HIV-1 vaccine field as a result of the
phase III Thai clinical trial [5], has pointed out in the direction
that poxvirus vectors are leading vaccine candidates against HIV-1
infection and that development of modified poxvirus vectors with
improved immunogenicity against HIV-1 antigens are needed.
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Materials and Methods
Ethics Statement
The animal studies were approved by the Ethical Committee of
Animal Experimentation (CEEA-CNB) of Centro Nacional de
Biotecnologia (CNB-CSIC) in accordance with national and
international guidelines and with the Royal Decree (RD 1201/
2005). Permit numbers: 152/07 and 080030.
Cells and viruses
Primary chicken embryo fibroblast cells (CEF) [7] and DF-1
cells (a spontaneously immortalized chicken embryo fibroblast cell
line. ATCC, Manassas, VA, Cat. no. CRL-12203) were grown in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% fetal calf serum (FCS). Cells were maintained in a humidified
air 5% CO2 atmosphere at 37uC (CEF) or 39uC (DF-1). Viral
infections were realized at 37uC in both cell lines. The poxvirus
strains used in this work included: modified vaccinia virus Ankara
(MVA) and the recombinant MVA-B expressing the HIV-1BX08
gp120 and HIV-1IIIB Gag-Pol-Nef proteins [7]. The parental and
recombinant MVA viruses were grown in CEF cells, similarly
purified through two 36% (w/v) sucrose cushions, and titrated by
plaque immunostaining assay as previously described [52].
Construction of plasmid transfer vectors pGem-RG-A41L
wm and pGem-RG-B16R wm
The plasmid transfer vector pGem-RG-A41L wm was used for
the construction of the recombinant virus MVA-B DA41L/
DB16R, with both A41L (A41L in Copenhagen strain of VACV is
equivalent to MVA 153L) and B16R (B16R in Copenhagen strain
of VACV is equivalent to MVA 184R) genes deleted, respectively
(for simplicity, we used throughout the work the ORF nomencla-
ture of Copenhagen strain to refer the MVA genes). pGem-RG-
A41L wm was obtained by the sequential cloning of five DNA
fragments containing dsRed2 and rsGFP genes and A41L
recombination flanking sequences into the plasmid pGem-7Zf(-)
(Promega). The dsRed2 gene under the control of the synthetic
early/late (E/L) promoter was amplified by PCR from plasmid
pG-dsRed2 with oligonucleotides Red2-B (59-GAACTAG-
GATCCTAACTCGAGAAA-39) (BamHI site underlined) and
Red2-N (59-ATTAGTATGCATTTATTTATTTAGG-39) (NsiI
site underlined) (785 bp), digested with BamHI and NsiI and
inserted into the BamHI/NsiI-digested pGem-7Zf(-) to generate
pGem-Red wm (3740 bp). The rsGFP gene under the control of
the synthetic E/L promoter was amplified by PCR from plasmid
pG-dsRed2 with oligonucleotides GFP-X (59-CGTTGGTCTA-
GAGAGAAAAATTG-39) (XbaI site underlined) and GFP-E (59-
CTATAGAATTCTCAAGCTATGC-39) (EcoRI site underlined)
(832 bp), digested with XbaI and EcoRI and inserted into plasmid
pGem-Red wm previously digested with XbaI and EcoRI to
obtain pGem-Red-GFP wm (4540 bp). MVA-B genome was used
as the template to amplify the right flank of A41L gene (389 bp)
with oligonucleotides RFA41L-AatII-F (59-CCTACTGACGT-
CATAAGCTATAATA-39) (AatII site underlined) and RFA41L-
XbaI-R (59-GATAATTCTAGATTGTTATTTTTAT-39) (XbaI
site underlined). This right flank was digested with AatII and XbaI
and cloned into plasmid pGem-Red-GFP wm previously digested
with the same restriction enzymes to generate pGem-RG-
RFsA41L wm (4896 bp). The repeated right flank of A41L gene
(389 bp) was amplified by PCR from MVA-B genome with
oligonucleotides RF9A41L-EcoRI-F (59-CCTACTGAATTCA-
TAAGCTATAATA-39) (EcoRI site underlined) and RF9A41L-
ClaI-R (59-GATAATATCGATTTGTTATTTTTAT-39) (ClaI
site underlined), digested with EcoRI and ClaI and inserted into
the EcoRI/ClaI-digested pGem-RG-RFsA41L wm to generate
pGem-RG-RFdA41L wm (5244 bp). The left flank of A41L gene
(404 bp) was amplified by PCR from MVA-B genome with
oligonucleotides LFA41L-ClaI-F (59-TAACGAATCGATTCTG-
CAATATTG-39) (ClaI site underlined) and LFA41L-BamHI-R
(59-GTGTTCGGATCCATTAGAGAGTTAG-39) (BamHI site
underlined), digested with ClaI and BamHI and inserted into
the ClaI/BamHI-digested pGem-RG-RFdA41L wm. The result-
ing plasmid pGem-RG-A41L wm (5618 bp) was confirmed by
DNA sequence analysis and directs the deletion of A41L gene from
MVA-B genome.
TheplasmidtransfervectorpGem-RG-B16Rwmwasusedforthe
construction of the recombinant virus MVA-B DA41L/DB16R, with
both A41L and B16R genes deleted, respectively. pGem-RG-B16R
wm was obtained by the sequential cloning of B16R recombination
flanking sequences into the plasmid pGem-Red-GFP wm (previously
described). MVA-B genome was used as the template to amplify the
leftflankofB16R gene (361 bp) with oligonucleotides LFB16R-AatII-
F( 5 9-CTTTTAGACGTCATGCGGAATTAGTG-39) (AatII site
underlined) and LFB16R-XbaI-R (59-TAGTATTCTAGATT-
TATTTTATAGTG-39) (XbaI site underlined). This left flank was
digested with AatII and XbaI and cloned into plasmid pGem-Red-
GFP wm previously digested with the same restriction enzymes to
generate pGem-RG-LFsB16R wm (4868 bp). The repeated left flank
of B16R gene (361 bp) was amplified by PCR from MVA-B ge-
nome with oligonucleotides LF9B16R-EcoRI-F (59-CTTTTA-
GAATTCATGCGGAATTAGTG-39) (EcoRI site underlined) and
LF9B16R-ClaI-R (59-TAGTATATCGATTTTATTTTATAGTG-
39) (ClaI site underlined), digested with EcoRI and ClaI and inserted
into the EcoRI/ClaI-digested pGem-RG-LFsB16R wm to generate
pGem-RG-LFdB16R wm (5188 bp). The right flank of B16R gene
(386 bp) was amplified by PCR from MVA-B genome with
oligonucleotides RFB16R-ClaI-F (59-AGTATAATCGATATGTA-
TGTTGTTAC-39) (ClaI site underlined) and RFB16R-BamHI-R
(59-TGTATCGGATCCCACCCTTTCCTAT-39)( B a m H Is i t eu n -
derlined), digested with ClaI and BamHI and inserted into the ClaI/
BamHI-digested pGem-RG-LFdB16R wm. The resulting plasmid
pGem-RG-B16R wm (5544 bp) was confirmed by DNA sequence
analysis and directs the deletion of B16R gene from MVA-B DA41L
genome.
Construction of MVA-B DA41L/DB16R deletion mutant
We first generated the single deletion mutant MVA-B DA41L
by screening for transient Red2/GFP co-expression [53] using
dsRed2 and rsGFP genes as the transiently selectable markers.
3610
6 DF-1 cells were infected with MVA-B at a multiplicity of
0.05 PFU/cell and then transfected 1h later with 6mg of DNA
from plasmid pGem-RG-A41L wm using Lipofectamine (Invitro-
gen, San Diego, CA) according to the manufacturer’s recommen-
dations. After 72h post-infection, the cells were harvested, lysed by
freeze-thaw cycling, sonicated and used for recombinant virus
screening. Deletion mutant was selected from progeny virus by 6
consecutive rounds of plaque purification in DF-1 cells and
plaques were screened for Red2/GFP fluorescence. In the first two
passages viruses from selected plaques expressed both fluorescent
proteins, in the next two passages viral progeny from selected
plaques expressed only one fluorescent marker (Red2 or GFP) and
in the last two passages (six passages in total) viruses from selected
plaques do not express any marker due to the loss of the
fluorescent marker. MVA-B DA41L was obtained and the deletion
of A41L gene was confirmed by PCR amplifying the A41L locus.
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constructed also by screening for transient Red2/GFP co-
expression, following the same protocol detailed above. 3610
6
DF-1 cells were infected with MVA-B DA41L at a multiplicity of
0.05 PFU/cell and then transfected 1h later with 6mg of DNA
from plasmid pGem-RG-B16R wm using Lipofectamine (Invitro-
gen, San Diego, CA). After 6 rounds of plaque purification MVA-
B DA41L/DB16R was obtained and the deletion of A41L and
B16R genes was confirmed by PCR amplifying the A41L and
B16R locus.
The resulting MVA-B DA41L/DB16R virus was grown in CEF
cells, purified by centrifugation through two 36% (w/v) sucrose
cushions in 10mM Tris-HCl pH 9, and titrated in DF-1 cells by
plaque immunostaining assay, using rabbit polyclonal antibody
against vaccinia virus strain WR (Centro Nacional de Biotecno-
logı ´a; diluted 1:1000) followed by anti-rabbit-HRP (Sigma; diluted
1:1000). MVA-B DA41L/DB16R deletion mutant generated were
free of contamination with mycoplasma (checked by specific PCR
for mycoplasma) or bacteria (checked by growth in LB plates
without ampicillin).
PCR analysis of MVA-B DA41L/DB16R deletion mutant
To test the purity of MVA-B DA41L/DB16R deletion mutant,
viral DNA was extracted from DF-1 cells mock-infected or
infected at 2 PFU/cell with MVA, MVA-B, or MVA-B DA41L/
DB16R. Primers RFA41L-AatII-F and LFA41L-BamHI-R (de-
scribed above) spanning A41L flanking regions were used for PCR
analysis of A41L locus. Primers LFB16R-AatII-F and RFB16R-
BamHI-R (described above) spanning B16R flanking regions were
used for PCR analysis of B16R locus. Both amplifications were
made in a total volume of 25ml containing 0.3mM of each
deoxynucleoside triphosphate, 0.3mM of each primer, 2mM
MgCl2, 50 to 100ng of DNA template, reaction buffer (16), and
1 unit of DNA polymerase Platinum Taq (Invitrogen). The PCR
protocol consisted of an initial step of 5 min at 94uC, followed by
35 cycles of 1 min at 94uC, 1 min at 50uC, and 1:30 min at 68uC.
The final extension cycle was 7 min at 72uC. PCR products were
resolved in 1% agarose gel in Tris-borate-EDTA (TBE) buffer
with 0.5mg/ml ethidium bromide and were visualized using UV
light. The deletions were also confirmed by DNA sequence
analysis.
Expression of HIV-1BX08 gp120 and HIV-1IIIB Gag-Pol-Nef
proteins by MVA-B DA41L/DB16R deletion mutant
To test the correct expression of HIV-1 proteins HIV-1BX08
gp120 and HIV-1IIIB Gag-Pol-Nef (GPN), monolayers of DF-1
cells were mock-infected or infected at 2 PFU/cell with MVA,
MVA-B or MVA-B DA41L/DB16R. At 24h post-infection, cells
were lysed in Laemmli buffer, cells extracts fractionated by 12%
SDS-PAGE and analyzed by Western blot using rabbit polyclonal
anti-gp120 antibody against IIIB (Centro Nacional de Biotecno-
logı ´a; diluted 1:3000) or polyclonal anti-gag p24 serum (ARP 432,
NIBSC, Centralised Facility for AIDS reagent, UK; diluted
1:3000) followed by anti-rabbit-HRP (Sigma; diluted 1:5000) to
evaluate the expression of gp120 and GPN proteins, respectively.
Analysis of virus growth
To determine virus-growth profiles, monolayers of DF-1 cells
grown in 12-well tissue culture plates were infected in duplicate at
0.01 PFU/cell with MVA-B or MVA-B DA41L/DB16R.
Following virus adsorption for 60 min at 37uC, the inoculum
was removed. The infected cells were washed once with DMEM
without serum and incubated with fresh DMEM containing 2%
FCS at 37uC in a 5% CO2 atmosphere. At different times post-
infection (0, 24, 48 and 72 hours), cells were collected by scraping,
freeze-thawed three times and briefly sonicated. The intracellular
viruses were titrated by immunostaining as described above.
Peptides
The HIV-1 peptide pools, with each purified peptide at 25mg
per vial, were provided by the EuroVacc Foundation. They
spanned the entire Env, Gag, Pol and Nef regions from clade B
included in the virus vectors as consecutive 15-mers overlapped by
11 amino acids. The HIV-1BX08 gp120 protein (494 aa) was
spanned by the Env-1 (aa: 1–251; 60 peptides) and Env-2 (aa:
241–494; 61 peptides) pools. The HIV-1IIIB Gag-Pol-Nef fusion
protein (1326 aa) was spanned by the following pools: Gag-1 (aa:
1–231; 55 peptides), Gag-2 (aa: 221–431; 50 peptides), GPN-1 (aa:
421–655; 56 peptides), GPN-2 (aa: 645–879; 56 peptides), GPN-3
(aa: 869–1103; 56 peptides) and GPN-4 (aa: 1093–1326; 56
peptides). For immunological analysis we grouped the peptides in
three main pools: Env, Gag and GPN. The Env-pool comprises
Env-1+Env-2; Gag-pool comprises Gag-1+Gag-2; and GPN-pool
comprises GPN-1+GPN-2+GPN-3+GPN-4. HIV-1 peptide Gag-
B (AMQMLKETI), from clade B, was produced at Centro
Nacional de Biotecnologı ´a.
Mice immunization schedule
BALB/c mice were purchased from Harlan. A DNA prime/
MVA boost immunization protocol was performed as previously
described [7]. Groups of animals (n=8) received 100mgo fD N A -
B( 5 0 mgo fp C M V - BX08gp120+50mgo fp C D N A - IIIBGPN) by
intramuscular route (i.m.) and two weeks later received an
intraperitoneal (i.p.) inoculation of 1610
7 PFU of the corre-
sponding recombinant vaccinia viruses (MVA-B or MVA-B
DA41L/DB16R) in 200 ml of PBS. At 11 and 53 days after the
last immunization 4 mice in each group were sacrificed and
spleens processed for fresh IFN-c ELISPOT and Intracellular
Cytokine Staining (ICS) assays, to measure the adaptive and
memory immune responses against HIV-1 antigens. Two
independent experiments have been performed for the different
groups.
Fresh IFN-c ELISPOT assay
Fresh IFN-c ELISPOT assay was performed as previously
described [54]. Briefly, 10
6 and 5610
5 splenocytes (depleted of red
blood cells) were plated in triplicate in 96-well nitrocellulose-
bottomed plates previously coated with 6mg/ml of anti-mouse
IFN-y mAb R4-6A2 (Pharmingen, San Diego, CA). HIV-1
peptide Gag-B from clade B was resuspended in RPMI 1640
supplemented with 10% FCS and added to the cells at a final
concentration of 10mg/ml. Cells were incubated at 37uC, 5% CO2
for 48h, washed extensively with PBS containing 0.05% of Tween
20 (PBS-T) and incubated 2h at room temperature (RT) with a
solution of 2mg/ml of biotinylated anti-mouse IFN-c mAb
XMG1.2 (Pharmingen, San Diego, CA) in PBS-T. Afterwards,
plates were washed with PBS-T and 100ml of peroxidase-labeled
avidin (Sigma, St. Louis, MO) at 1:800 dilution in PBS-T was
added to each well. After 1h of incubation at RT, wells were
washed with PBS-T and PBS. The spots were developed by adding
1mg/ml of the substrate 3,39-diaminobenzidine tetrahydrochloride
(Sigma, St. Louis, MO) in 50mM Tris–HCl, pH 7.5 containing
0.015% hydrogen peroxide. The spots were counted with the aid
of a stereomicroscope. Values are reported after the subtraction of
background (cells with RPMI) and expressed as net spot-forming
units per 10
6 splenocytes.
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The phenotypes of responding T cells were analyzed by ICS
and fluorescence-activated cell sorting analysis as described
elsewhere [3]. After an overnight rest, 5610
6 splenocytes
(depleted of red blood cells) were resuspended in RPMI 1640
supplemented with 10% FCS and containing 1ml/ml Golgiplug
(BD Biosciences) to inhibit cytokine secretion. Cells were seeded
on M96 plates and stimulated with Gag-B peptide, Env-, Gag- or
GPN-pools added to the cells at a final concentration of 5mg/ml.
Cells were incubated at 37uC, 5% CO2, and then analyzed by
ICS. After 6h of stimulation, cells were washed, stained for the
surface markers, fixed, permeabilized using the BD Cytofix/
Cytoperm
TM Kit (Becton Dickinson) and stained intracellularly
using the appropriate fluorochromes. To analyze the adaptive
immune responses, the following fluorochrome-conjugated anti-
bodies were used: CD3-FITC, CD4-Alexa 700, CD8-PerCP, IL-
2-PE, IFN-c-APC and TNF-a-PECY-7. For memory analyses,
the following antibodies were used: CD4-Alexa 700, CD8-FITC,
IFN-c-PECY-7 and IL-2-Alexa-647. All antibodies were from BD
Biosciences. Cells were acquired using an LSRII flow cytometer
(Becton Dickinson) equipped with a high throughput system. The
number of events ranged between 10
5 and 10
6. Dead cells were
excluded using the violet LIVE/DEAD stain kit (Invitrogen).
Lymphocytes were gated on a forward scatter area versus side
scatter area pseudo-color dot plot. To analyze the adaptive
immune responses, CD4
+ and CD8
+ events (gate previously on
CD3
+ cells) were gated versus IFN-c,T N F - a and IL-2, and then
combined together using the boolean operator. For memory
analyses, CD4
+ and CD8
+ eventsweregated versusIFN-c andIL-
2, and then combined together using the boolean operator.
Sample analysis was performed using FlowJo version 8.5.3 (Tree
S t a r ,A s h l a n d ,O R ) .
Antibody measurements by Enzyme-linked
Immunosorbent Assay (ELISA)
Antibodies anti-HIV-1 gp160LAV envelope protein were
measured by ELISA as previously described [7]. Briefly, high
binding polystyrene microtitre plates (Nunc) were coated with
100ml of the purified HIV-1 gp160LAV envelope protein (Protein
Sciences) diluted at 2mg/ml in 0.05M carbonate–bicarbonate
buffer pH 9.6 overnight at 4uC. The wells were washed twice with
PBS-T and blocked with PBS containing 10% FCS (blocking
solution) during 1h at 37uC. Serum samples diluted 1/100 in
blocking solution were added in a volume of 100ml/well and
incubated 2h at 37uC. Plates were washed three times with PBS-T
before the detection antibody was added. Peroxidase-conjugated
goat anti-mouse immunoglobulin G (IgG) antibody (Southern
Biotechnology Associated, Birmingham, Ala) was diluted 1:1000 in
PBS-T and incubated for 1h at 37uC. The plates were washed
again three times with PBS-T and 3,39,5,59 Tetramethylbenzidine
(TMB) (Sigma) was used to reveal the reaction. After 10–15 min of
incubation at RT, the reaction was stopped by adding 2N H2SO4,
and absorbance was measured at 450nm on a Multiskan Plus plate
reader (Labsystem, Chicago, Ill).
Statistical procedures
For the statistical analysis, we have developed a novel approach
that corrects measurements for the medium response (RPMI) and
at the same time it allows the exact calculation of confidence
intervals and p-values of hypothesis tests. For ELISPOT and ICS
statistical analysis, it was proceeded as previously described [55].
Given the total number of cells, NT, and the number of cells
responding to a given antigen, NAg, an estimate of the proportion
of cells responding to this antigen is given by ^ p pAg~
NAg
NT
.T h e
Bayesian a posteriori distribution of ^ p pAg without any ap r i o r iassumption
(i.e., assuming that the true proportion is uniformly distributed
between 0 and 1) is the Beta distribution with parameters
(NAgz1,NT{NAgz1) [56]. Let us call f^ p pAg(x) the corresponding
probability density function ap o st e r io r i . Analogously, we can derive the
distribution of the proportion of cells responding to RPMI, obtaining
the distribution f^ p pRPMI(x). To test whether the antigen response is
significantly larger than the RPMI response, we computed the
probability density function of the variable ^ p pAgCorrected~^ p pAg{^ p pRPMI
as f^ p pAgCorrected(x)~
ð ?
{?
f^ p pAg(x)f^ p pRPMI(xzx)dx. The cumulative density
function of this variable is defined in the usual way
F^ p pAgCorrected(x)~
ð x
{?
f^ p pAgCorrected(x)dx.T h ea percentile of this variable
is defined as xa such that F^ p pAgCorrected(xa)~a.W ec o m p u t e dt h e
symmetric 95% confidence interval for the RPMI corrected
proportion as ½x0:025,x0:975 .F i n a l l y ,w ec o n s i d e r^ p pAg to be
significantly larger than ^ p pRPMI if x0:025w0.I ns u c hac a s e ,
½x0:025,x0:975  gives the 95% symmetric confidence interval for
^ p pAgCorrected.T h ea v e r a g e^ p pAgCorrected is computed as the expected
value of f^ p pAgCorrected(x) (note that this expected value needs not be in
the middle of the confidence interval,
x0:025zx0:975
2
). Whenever two
corrected proportions need to be summed, ^ p pAgCorrected1z2~
^ p pAgCorrected1z^ p pAgCorrected2, we convolved their probability density
functions to obtain the probability density function of the summed
proportion, f^ p pAgCorrected1z2(x)~
ð ?
{?
f^ p pAgCorrected1(x)f^ p pAgCorrected2(x{x)dx,i n
this way confidence intervals for any sum of corrected proportions
can be obtained. Antigen responses were not added unless each
component was significantly larger than the corresponding RPMI.
In the ELISPOT experiment, three replicates were obtained for
each kind of antigen. The average response to that antigen was
computed using only the corrected proportions significantly larger
than the corresponding RPMI. The division implied by the
averaging process needed a reinterpolation of the probability
density function which we carried out using cubic splines as
implemented in MATLAB 2008a.
Supporting Information
Table S1 Comparative HIV-1-specific immune responses elic-
ited in different animal models and humans using DNA prime/
poxvirus boost (MVA or NYVAC) immunization protocols from
the EuroVacc trials. The induction of HIV-1-specific immune
responses measure by ELISPOT and ICS after boost with
different poxvirus vectors (MVA or NYVAC) in different animal
models (mice or non-human primates) or humans (Phase I clinical
trials) is indicated. The different DNA and recombinant poxvirus
used in the prime/boost contains different HIV-1 genes (Env,
Gag, Pol and Nef) from different clades (B or C), and are indicated
in the corresponding row. HIV-1-specific IFN-c secreting cells are
measured by ELISPOT, and the magnitude and breath induced
are indicated. HIV-1-specific CD4+ and CD8+ T cells are
measured by ICS, and the magnitude, breath and polyfuncionality
induced are indicated. ND, not determine.
Found at: doi:10.1371/journal.pone.0012395.s001 (0.08 MB
DOC)
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